Immutep Limited (IMMP)

AU — Healthcare Sector
Peers: CWBR  OCEA  ELEV  AVRO  ZURA    CNSP  ZVSA  EFTR  VECT  ENVB 

Automate Your Wheel Strategy on IMMP

With Tiblio's Option Bot, you can configure your own wheel strategy including IMMP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IMMP
  • Rev/Share 0.0034
  • Book/Share 0.1187
  • PB 2.4117
  • Debt/Equity 0.0098
  • CurrentRatio 18.8628
  • ROIC -0.5521

 

  • MktCap 416671190.3425
  • FreeCF/Share -0.032
  • PFCF -8.9733
  • PE -9.4824
  • Debt/Assets 0.0092
  • DivYield 0
  • ROE -0.2424

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 2
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Immutep Limited: Surging On Positive Head And Neck Data
IMMP
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive

Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues. Despite promising phase 2 data, the fate of eftilagimod remains uncertain, with future trials and FDA discussions critical for potential accelerated approval.

Read More
image for news Immutep Limited: Surging On Positive Head And Neck Data

About Immutep Limited (IMMP)

  • IPO Date 2012-04-19
  • Website https://www.immutep.com
  • Industry Biotechnology
  • CEO Mr. Marc Voigt
  • Employees 41
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.